Published on 10 May 2024 on Simply Wall St. via Yahoo Finance
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its...
Mersana Therapeutics, Inc. (NASDAQ:MRSN) just released its quarterly report and things are looking bullish. Revenues of US$9.2m were better than expected, some 12% ahead of forecasts. The company still lost a statutory US$0.16 per share, although the losses were 14% smaller than the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
See our latest analysis for Mersana Therapeutics
